<p>先锋集团有限公司 (IRSH)</p>
<p>表格 8.3 - 先锋集团有限公司：Avadel Pharmaceuticals plc</p>
<p>2025 年 12 月 31 日/ 15:22 GMT/BST</p>
<p>Ap27</p>
<p>表格 8.3</p>
<p>爱尔兰收购委员会</p>
<p>开盘位置披露/根据 1997 年爱尔兰收购委员会法第 8.3 条的交易披露</p>
<p>规则，2022 年由持有相关证券 1% 或以上利益的人员提供</p>
<ol>
<li>关键信息</li>
</ol>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- 披露者全名</td>
<td>先锋集团有限公司</td>
</tr>
<tr>
<td>- 如果与 1(a) 不同，利益和空头头寸的所有者或控制者</td>
<td></td>
</tr>
<tr>
<td>提名或车辆公司的命名是不够的。对于信托，必须命名受托人、设立人和受益人。</td>
<td></td>
</tr>
<tr>
<td>- 与本表相关的要约方/受要约方的名称</td>
<td></td>
</tr>
<tr>
<td>请为每个要约方/受要约方使用单独的表格</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>- 如果是与要约方/受要约方相关的豁免基金经理，请说明并指定要约方/受要约方的身份（注 1）</td>
<td></td>
</tr>
<tr>
<td>- 持有头寸/进行交易的日期</td>
<td></td>
</tr>
<tr>
<td>对于开盘位置披露，请说明披露前的最新可行日期</td>
<td>2025 年 12 月 30 日</td>
</tr>
<tr>
<td>- 除上述 1(c) 中的公司外，披露者是否还在对任何其他要约方进行披露？</td>
<td></td>
</tr>
<tr>
<td>如果是现金要约或可能的现金要约，请说明 “N/A”</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<ol>
<li>利益和空头头寸</li>
</ol>
<p>如果要披露的要约方或受要约方在 1(c) 中列出的相关证券的多个类别中存在利益和空头头寸，请为每个额外类别复制表 2。</p>
<p>Ap28</p>
<p>与披露相关的要约方或受要约方的相关证券的利益和空头头寸（如有）</p>
<p>（注 2）</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>（注 3）</td>
<td>0.01 美元普通股</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>利益</td>
<td>空头头寸</td>
<td></td>
<td></td>
</tr>
<tr>
<td>数量</td>
<td>%</td>
<td>数量</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>- 拥有和/或控制的相关证券</td>
<td>5,864,542</td>
<td>5.97%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- 现金结算衍生品</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- 股票结算衍生品（包括期权）和购买/出售协议</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>总计</td>
<td>5,864,542</td>
<td>5.97%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>所有利益和所有空头头寸应予以披露。</p>
<p>包括认购新证券的权利和任何未平仓的股票结算衍生品头寸（包括交易期权）或购买或出售相关证券的协议的选项详细信息，应在补充表格 8 中提供。</p>
<ol>
<li>披露者的交易（如有）（注 4）</li>
</ol>
<p>如果在 1(c) 中列出的要约方或受要约方的多个类别的相关证券中有交易，请为每个额外类别复制表 3(a)、(b)、(c) 或 (d)（视情况而定）。</p>
<p>所有价格和其他货币金额的货币应予以说明。</p>
<p>(a) 购买和销售</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>购买/销售</td>
<td>证券数量</td>
<td>每单位价格</td>
</tr>
<tr>
<td>（注 5）</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.01 美元普通股</td>
<td>购买</td>
<td>610</td>
<td>21.54 美元</td>
</tr>
<tr>
<td>0.01 美元普通股</td>
<td>出售</td>
<td>306</td>
<td>21.54 美元</td>
</tr>
</tbody>
</table>
<p>Ap29</p>
<p>(b) 现金结算衍生品交易</p>
<ul>
<li>相关证券类别</li>
<li>产品描述，例如 CFD</li>
<li>交易性质，例如开立/平仓多头/空头头寸，增加/减少多头/空头头寸</li>
<li>参考证券数量（注 6）</li>
<li>每单位价格（注 5）</li>
</ul>
<p>(c) 股票结算衍生品交易（包括期权）</p>
<p>(i) 写入、出售、购买或变更</p>
<ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>写入、购买、出售、变更等。</li>
<li>与期权相关的证券数量（注 6）</li>
<li>每单位行使价格</li>
<li>类型，例如美式、欧式等。</li>
<li>到期日</li>
<li>每单位支付/收到的期权金额</li>
</ul>
<p>(ii) 行使</p>
<ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>行使/已行使</li>
<li>证券数量</li>
<li>每单位行使价格（注 5）</li>
</ul>
<p>(d) 其他交易（包括新证券的交易）（注 3）</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>不适用</td>
</tr>
<tr>
<td>交易性质</td>
<td></td>
</tr>
<tr>
<td>例如：认购、</td>
<td></td>
</tr>
<tr>
<td>转换、行使</td>
<td></td>
</tr>
<tr>
<td>详细信息</td>
<td></td>
</tr>
<tr>
<td>每单位价格（如</td>
<td></td>
</tr>
<tr>
<td>适用）</td>
<td></td>
</tr>
<tr>
<td>（注 5）</td>
<td></td>
</tr>
</tbody>
</table>
<p>Ap30</p>
<ol>
<li>其他信息</li>
</ol>
<p>(a) 赔偿和其他交易安排</p>
<ul>
<li>任何赔偿或期权安排的详细信息，或与相关证券有关的任何协议或理解，无论是正式还是非正式，可能会诱使披露者与要约方或与要约方一致行动的任何人进行交易或避免交易。不可撤销的承诺和意向书不应包括。如果没有此类协议、安排或理解，请说明 “无”。</li>
<li>无</li>
</ul>
<p>(b) 与期权或衍生品相关的协议、安排或理解</p>
<ul>
<li>披露者与任何其他人之间的任何协议、安排或理解的完整详细信息，涉及本表中提到的任何期权下的相关证券的投票权，或涉及本表中提到的任何衍生品的相关证券的投票权或未来的收购或处置。如果没有，应说明。</li>
<li>无</li>
</ul>
<p>(c) 附件</p>
<ul>
<li>是否附有补充表格 8？</li>
<li>否</li>
</ul>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期</td>
<td>2025 年 12 月 31 日</td>
</tr>
<tr>
<td>联系人姓名</td>
<td>Shawn Acker</td>
</tr>
<tr>
<td>电话号码</td>
<td>001-610-669-6713</td>
</tr>
</tbody>
</table>
<p>根据规则 8.3 的公开披露必须向监管信息服务进行。
监管公告的传播由 EQS Group 传输。发行人对本公告的内容负全部责任。</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>分类代码：</td>
<td>RET - Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>TIDM:</td>
<td>IRSH</td>
</tr>
<tr>
<td>LEI 代码：</td>
<td>5493002789CX3L0CJP65</td>
</tr>
<tr>
<td>序列号：</td>
<td>413342</td>
</tr>
<tr>
<td>EQS 新闻 ID:</td>
<td>2253326</td>
</tr>
</tbody>
</table>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>公告结束</td>
<td>EQS 新闻服务</td>
</tr>
</tbody>
</table>
<p><strong>免责声明</strong></p>
<p>在商业背景下将新闻保存到数据库或将新闻转发给第三方，只有在获得 EQS Group AG 事先书面同意的情况下才被允许。</p>

Avadel制药

<p>先锋集团（The Vanguard Group, Inc.）根据爱尔兰收购委员会的规定披露了其在 Avadel 制药（Avadel Pharmaceuticals plc）中的持股情况。截至 2025 年 12 月 30 日，先锋集团持有 5,864,542 股普通股，占公司总股本的 5.97%。最近的交易包括购买 610 股和出售 306 股，交易价格均为每股 21.54 美元。该披露于 2025 年 12 月 31 日发布，未报告任何其他协议或安排</p>

<p>The Vanguard Group, Inc. (IRSH)</p>
<div class="lb-trans"><p>先锋集团有限公司 (IRSH)</p>
</div><p>Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc</p>
<div class="lb-trans"><p>表格 8.3 - 先锋集团有限公司：Avadel Pharmaceuticals plc</p>
</div><p>31-Dec-2025 / 15:22 GMT/BST</p>
<div class="lb-trans"><p>2025 年 12 月 31 日/ 15:22 GMT/BST</p>
</div><p>Ap27</p>
<div class="lb-trans"><p>Ap27</p>
</div><p>FORM 8.3</p>
<div class="lb-trans"><p>表格 8.3</p>
</div><p>IRISH TAKEOVER PANEL</p>
<div class="lb-trans"><p>爱尔兰收购委员会</p>
</div><p>OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER</p>
<div class="lb-trans"><p>开盘位置披露/根据 1997 年爱尔兰收购委员会法第 8.3 条的交易披露</p>
</div><p>RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE</p>
<div class="lb-trans"><p>规则，2022 年由持有相关证券 1% 或以上利益的人员提供</p>
</div><p>1. KEY INFORMATION</p>
<div class="lb-trans"><ol>
<li>关键信息</li>
</ol>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- Full name of discloser</td>
<td>The Vanguard Group, Inc.</td>
</tr>
<tr>
<td>- Owner or controller of interests and short positions disclosed, if different from 1(a) <br/>The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.</td>
<td></td>
</tr>
<tr>
<td>- Name of offeror/offeree in relation to whose relevant securities this form relates <br/>Use a separate form for each offeror/offeree</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>- If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)</td>
<td></td>
</tr>
<tr>
<td>- Date position held/dealing undertaken <br/>For an opening position disclosure, state the latest practicable date prior to the disclosure</td>
<td>30 December 2025</td>
</tr>
<tr>
<td>- In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer? <br/>If it is a cash offer or possible cash offer, state “N/A”</td>
<td>N/A</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>- 披露者全名</td>
<td>先锋集团有限公司</td>
</tr>
<tr>
<td>- 如果与 1(a) 不同，利益和空头头寸的所有者或控制者</td>
<td></td>
</tr>
<tr>
<td>提名或车辆公司的命名是不够的。对于信托，必须命名受托人、设立人和受益人。</td>
<td></td>
</tr>
<tr>
<td>- 与本表相关的要约方/受要约方的名称</td>
<td></td>
</tr>
<tr>
<td>请为每个要约方/受要约方使用单独的表格</td>
<td>Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>- 如果是与要约方/受要约方相关的豁免基金经理，请说明并指定要约方/受要约方的身份（注 1）</td>
<td></td>
</tr>
<tr>
<td>- 持有头寸/进行交易的日期</td>
<td></td>
</tr>
<tr>
<td>对于开盘位置披露，请说明披露前的最新可行日期</td>
<td>2025 年 12 月 30 日</td>
</tr>
<tr>
<td>- 除上述 1(c) 中的公司外，披露者是否还在对任何其他要约方进行披露？</td>
<td></td>
</tr>
<tr>
<td>如果是现金要约或可能的现金要约，请说明 “N/A”</td>
<td>N/A</td>
</tr>
</tbody>
</table>
</div><p>2. INTERESTS AND SHORT POSITIONS</p>
<div class="lb-trans"><ol>
<li>利益和空头头寸</li>
</ol>
</div><p>If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.</p>
<div class="lb-trans"><p>如果要披露的要约方或受要约方在 1(c) 中列出的相关证券的多个类别中存在利益和空头头寸，请为每个额外类别复制表 2。</p>
</div><p>Ap28</p>
<div class="lb-trans"><p>Ap28</p>
</div><p>Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)</p>
<div class="lb-trans"><p>与披露相关的要约方或受要约方的相关证券的利益和空头头寸（如有）</p>
</div><p>(Note 2)</p>
<div class="lb-trans"><p>（注 2）</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security <br/>(Note 3)</td>
<td>US$0.01 ordinary shares</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interests</td>
<td>Short positions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number</td>
<td>%</td>
<td>Number</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>- Relevant securities owned and/or controlled</td>
<td>5,864,542</td>
<td>5.97%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Cash-settled derivatives</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Stock-settled derivatives (including options) and agreements to purchase/ sell</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>5,864,542</td>
<td>5.97%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>（注 3）</td>
<td>0.01 美元普通股</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>利益</td>
<td>空头头寸</td>
<td></td>
<td></td>
</tr>
<tr>
<td>数量</td>
<td>%</td>
<td>数量</td>
<td>%</td>
<td></td>
</tr>
<tr>
<td>- 拥有和/或控制的相关证券</td>
<td>5,864,542</td>
<td>5.97%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- 现金结算衍生品</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- 股票结算衍生品（包括期权）和购买/出售协议</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>总计</td>
<td>5,864,542</td>
<td>5.97%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div><p>All interests and all short positions should be disclosed.</p>
<div class="lb-trans"><p>所有利益和所有空头头寸应予以披露。</p>
</div><p>Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.</p>
<div class="lb-trans"><p>包括认购新证券的权利和任何未平仓的股票结算衍生品头寸（包括交易期权）或购买或出售相关证券的协议的选项详细信息，应在补充表格 8 中提供。</p>
</div><p>3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)</p>
<div class="lb-trans"><ol>
<li>披露者的交易（如有）（注 4）</li>
</ol>
</div><p>Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.</p>
<div class="lb-trans"><p>如果在 1(c) 中列出的要约方或受要约方的多个类别的相关证券中有交易，请为每个额外类别复制表 3(a)、(b)、(c) 或 (d)（视情况而定）。</p>
</div><p>The currency of all prices and other monetary amounts should be stated.</p>
<div class="lb-trans"><p>所有价格和其他货币金额的货币应予以说明。</p>
</div><p>(a) Purchases and sales</p>
<div class="lb-trans"><p>(a) 购买和销售</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of relevant security</td>
<td>Purchase/sale</td>
<td>Number of securities</td>
<td>Price per unit<br/>(Note 5)</td>
</tr>
<tr>
<td>US$0.01 ordinary shares</td>
<td>Purchase</td>
<td>610</td>
<td>21.54 USD</td>
</tr>
<tr>
<td>US$0.01 ordinary shares</td>
<td>Sale</td>
<td>306</td>
<td>21.54 USD</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>购买/销售</td>
<td>证券数量</td>
<td>每单位价格</td>
</tr>
<tr>
<td>（注 5）</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0.01 美元普通股</td>
<td>购买</td>
<td>610</td>
<td>21.54 美元</td>
</tr>
<tr>
<td>0.01 美元普通股</td>
<td>出售</td>
<td>306</td>
<td>21.54 美元</td>
</tr>
</tbody>
</table>
</div><p>Ap29</p>
<div class="lb-trans"><p>Ap29</p>
</div><p>(b) Cash-settled derivative transactions</p>
<div class="lb-trans"><p>(b) 现金结算衍生品交易</p>
</div><ul>
<li>Class ofrelevantsecurity</li>
<li>Product description e.g. CFD</li>
<li>Nature of dealinge.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position</li>
<li>Number ofreference securities (Note 6)</li>
<li>Price per unit (Note 5)</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述，例如 CFD</li>
<li>交易性质，例如开立/平仓多头/空头头寸，增加/减少多头/空头头寸</li>
<li>参考证券数量（注 6）</li>
<li>每单位价格（注 5）</li>
</ul>
</div><p>(c) Stock-settled derivative transactions (including options)</p>
<div class="lb-trans"><p>(c) 股票结算衍生品交易（包括期权）</p>
</div><p>(i) Writing, selling, purchasing or varying</p>
<div class="lb-trans"><p>(i) 写入、出售、购买或变更</p>
</div><ul>
<li>Class of relevant security</li>
<li>Product description e.g. call option</li>
<li>Writing, purchasing, selling, varying etc.</li>
<li>Number of securities to which option relates (Note 6)</li>
<li>Exerciseprice per unit</li>
<li>Type e.g. American, Europeanetc.</li>
<li>Expiry date</li>
<li>Option moneypaid/ received per unit</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>写入、购买、出售、变更等。</li>
<li>与期权相关的证券数量（注 6）</li>
<li>每单位行使价格</li>
<li>类型，例如美式、欧式等。</li>
<li>到期日</li>
<li>每单位支付/收到的期权金额</li>
</ul>
</div><p>(ii) Exercise</p>
<div class="lb-trans"><p>(ii) 行使</p>
</div><ul>
<li>Class of relevant security</li>
<li>Product description e.g. call option</li>
<li>Exercising/ exercised against</li>
<li>Number of securities</li>
<li>Exercise price per unit (Note 5)</li>
</ul>
<div class="lb-trans"><ul>
<li>相关证券类别</li>
<li>产品描述，例如看涨期权</li>
<li>行使/已行使</li>
<li>证券数量</li>
<li>每单位行使价格（注 5）</li>
</ul>
</div><p>(d) Other dealings (including transactions in respect of new securities) (Note 3)</p>
<div class="lb-trans"><p>(d) 其他交易（包括新证券的交易）（注 3）</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Class of <br/>relevant <br/>security</td>
<td>Not Applicable</td>
</tr>
<tr>
<td>Nature of dealing <br/>e.g. subscription, <br/>conversion, exercise</td>
<td></td>
</tr>
<tr>
<td>Details</td>
<td></td>
</tr>
<tr>
<td>Price per unit (if <br/>applicable) <br/>(Note 5)</td>
<td></td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>相关证券类别</td>
<td>不适用</td>
</tr>
<tr>
<td>交易性质</td>
<td></td>
</tr>
<tr>
<td>例如：认购、</td>
<td></td>
</tr>
<tr>
<td>转换、行使</td>
<td></td>
</tr>
<tr>
<td>详细信息</td>
<td></td>
</tr>
<tr>
<td>每单位价格（如</td>
<td></td>
</tr>
<tr>
<td>适用）</td>
<td></td>
</tr>
<tr>
<td>（注 5）</td>
<td></td>
</tr>
</tbody>
</table>
</div><p>Ap30</p>
<div class="lb-trans"><p>Ap30</p>
</div><p>4. OTHER INFORMATION</p>
<div class="lb-trans"><ol>
<li>其他信息</li>
</ol>
</div><p>(a) Indemnity and other dealing arrangements</p>
<div class="lb-trans"><p>(a) 赔偿和其他交易安排</p>
</div><ul>
<li>Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer. Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”</li>
<li>none</li>
</ul>
<div class="lb-trans"><ul>
<li>任何赔偿或期权安排的详细信息，或与相关证券有关的任何协议或理解，无论是正式还是非正式，可能会诱使披露者与要约方或与要约方一致行动的任何人进行交易或避免交易。不可撤销的承诺和意向书不应包括。如果没有此类协议、安排或理解，请说明 “无”。</li>
<li>无</li>
</ul>
</div><p>(b) Agreements, arrangements or understandings relating to options or derivatives</p>
<div class="lb-trans"><p>(b) 与期权或衍生品相关的协议、安排或理解</p>
</div><ul>
<li>Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.</li>
<li>none</li>
</ul>
<div class="lb-trans"><ul>
<li>披露者与任何其他人之间的任何协议、安排或理解的完整详细信息，涉及本表中提到的任何期权下的相关证券的投票权，或涉及本表中提到的任何衍生品的相关证券的投票权或未来的收购或处置。如果没有，应说明。</li>
<li>无</li>
</ul>
</div><p>(c) Attachments</p>
<div class="lb-trans"><p>(c) 附件</p>
</div><ul>
<li>Is a Supplemental Form 8 attached?</li>
<li>No</li>
</ul>
<div class="lb-trans"><ul>
<li>是否附有补充表格 8？</li>
<li>否</li>
</ul>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of disclosure</td>
<td>31 December 2025</td>
</tr>
<tr>
<td>Contact name</td>
<td>Shawn Acker</td>
</tr>
<tr>
<td>Telephone number</td>
<td>001-610-669-6713</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>披露日期</td>
<td>2025 年 12 月 31 日</td>
</tr>
<tr>
<td>联系人姓名</td>
<td>Shawn Acker</td>
</tr>
<tr>
<td>电话号码</td>
<td>001-610-669-6713</td>
</tr>
</tbody>
</table>
</div><p>Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
Dissemination of a Regulatory Announcement, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.</p>
<div class="lb-trans"><p>根据规则 8.3 的公开披露必须向监管信息服务进行。
监管公告的传播由 EQS Group 传输。发行人对本公告的内容负全部责任。</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Category Code:</td>
<td>RET - Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>TIDM:</td>
<td>IRSH</td>
</tr>
<tr>
<td>LEI Code:</td>
<td>5493002789CX3L0CJP65</td>
</tr>
<tr>
<td>Sequence No.:</td>
<td>413342</td>
</tr>
<tr>
<td>EQS News ID:</td>
<td>2253326</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>分类代码：</td>
<td>RET - Avadel Pharmaceuticals plc</td>
</tr>
<tr>
<td>TIDM:</td>
<td>IRSH</td>
</tr>
<tr>
<td>LEI 代码：</td>
<td>5493002789CX3L0CJP65</td>
</tr>
<tr>
<td>序列号：</td>
<td>413342</td>
</tr>
<tr>
<td>EQS 新闻 ID:</td>
<td>2253326</td>
</tr>
</tbody>
</table>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>End of Announcement</td>
<td>EQS News Service</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>公告结束</td>
<td>EQS 新闻服务</td>
</tr>
</tbody>
</table>
</div><p><strong>Disclaimer</strong></p>
<div class="lb-trans"><p><strong>免责声明</strong></p>
</div><p>Saving the news in databases or any forwarding of the news to third parties in a commercial context or for commercial purposes is only permitted with the prior written consent of EQS Group AG.</p>
<div class="lb-trans"><p>在商业背景下将新闻保存到数据库或将新闻转发给第三方，只有在获得 EQS Group AG 事先书面同意的情况下才被允许。</p>
</div>

表格 8.3 - Vanguard 集团公司：Avadel 制药公司